Dignitana nominated for inaugural Texas Impact Enterprise Awards

Files for download
Dignitana Release - wkr0006.pdf

Dignitana announces that it has been nominated for the inaugural Texas Impact Enterprise Awards. The award recognizes organizations that strategically utilize business practices and leverage market forces to make a positive, meaningful impact in the community.

Dignitana manufactures and markets the clinically superior DigniCap Scalp Cooling System to minimize hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate, and gynecological cancers. FDA cleared since 2015, DigniCap provides a significant quality of life improvement for thousands of patients each year.

“We appreciate this recognition of our commitment to innovation and excellence as we continue to grow our business to provide DigniCap to even more patients,” said Catarina Löwenadler, Dignitana CEO. Our latest generation of the Swedish innovation DigniCap Delta is unique on the market, powered by efficient thermoelectric cooling, and manufactured in Dallas, USA.

Presented by The Hunt Institute for Engineering & Humanity of Southern Methodist University, the Inclusive Economy Consortium and their partners, the award program was launched this year to shine a spotlight on the heart of social and environmental impact leaders in Texas, recognizing those who prove that impact enterprises can be a force for good and have the greatest potential for scaled impact.

Scalp cooling is recognized internationally as a standard of care and quality of life advancement for cancer patients and is listed as a treatment recommendation in the clinical practice guidelines published by  National Comprehensive Cancer Network® (NCCN®), European Society for Medical Oncology (ESMO), and Cancer Australia.

For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com